Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Compound 386** is an investigational traditional Chinese multi-herb formula, also called Nourishing Liver and Kidney Compound 386, being developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine and Shanghai University of Traditional Chinese Medicine for hepatitis B virus-related decompensated cirrhosis. The formula is derived from *Xu Ming Yi Lei An* and publicly reported components include rehmannia root, glehnia root, ophiopogon root, and angelica root. It is being evaluated as Compound 386 granules in a randomized, double-blind, placebo-controlled, multicenter clinical study, alongside antiviral therapy, with overall survival and safety as principal objectives. ([chictr.org.cn](https://www.chictr.org.cn/showproj.html?proj=201447))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound 386.